Gulbarga
| Sl. No. | Principal Investigator’s Name | Study Title | Phase | Protocol ID | Indication | Study Status | Contact person & Phone Number |
|---|---|---|---|---|---|---|---|
| 1 | Dr Nandish Kumar | “A Global, multicentre, three arms, and open-label randomized study to evaluate the efficacy and safety of Nanosomal Docetaxel Lipid Suspension Compared to Taxotere (Docetaxel Injection Concentrate) in triple – negative breast cancer patients with locally advanced or metastatic breast cancer after failure to prior chemotherapy.” | TNBC | Ongoing | Dr Abhishek 9902040230 | ||
| 2 | Dr Nandish Kumar | A Phase IIb/III, Randomised, Double-blind, Placebo-controlled, Multicentre, Study of CA-170 in Combination with Chemotherapy and Radiation in Patients with Unresectable Stage III or IVa Non-Squamous Non-Small Cell Lung Cancer (ASIAD-2)” | Phase 2b/3 | CA-170-302 | NSCLC | Ongoing | Dr Abhishek 9902040230 |
| 3 | Dr Nandish Kumar | A Phase 3, Open-label, Randomized study of Dato-DXd versus Investigator’s choice of chemothetapy in participants with inoperable or Metastatic Hormone Receptor-Positive, HER-2 Negative breast cancer who have beentreated with one or two prior lines of Systemic Chemotherapy (TROPION-Breast01) | Phase 3 | D9268C00001 | ER+ve HER-Ve | SIV Pending | Dr Abhishek 9902040230 |
| 4 | Dr Nandish Kumar | A Phase II Open-Label Trial Evaluating the Efficacy and Safety of Once Daily Oral ODM-203 in Patients with Unresectable Transitional Cell Urothelial Carcinoma with FGFR3 Mutation (TEJAS-1) | Phase 2 | ODM-201 | Ca Ovary | EC Pending | Dr Abhishek 9902040230 |
